Dr Bruce Burlington joins AZ board

pharmafile | July 30, 2010 | Appointment | Research and Development, Sales and Marketing AstraZeneca, appointment, research and development, sales and marketing 

AstraZeneca has appointed former FDA staffer Dr Bruce Burlington to its board as a non-executive director.

Dr Burlington spent 17 years with the FDA, serving as director of the US regulator’s Center for Devices and Radiological Health for six years in the 1990s as well as holding a number of senior roles in the Center for Drug Evaluation and Research.

Following this he moved into the pharma industry, serving in a series of senior executive positions at Wyeth (now part of Pfizer).

These included executive VP of business practices and compliance, executive VP of quality, regulatory, safety, compliance and audit, and senior VP of regulatory affairs and quality.

Dr Burlington is currently a pharmaceutical product development and regulatory affairs consultant, a non-executive director of Cangene Corporation and a member of the scientific advisory boards of the International Medica Foundation and Lundbeck.

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have …

Latest content